Angiogenesis and inflammation in ductal carcinoma in situ of the breast

Several recent studies suggest that vascular density may be an independent prognostic indicator in invasive carcinoma of the breast. Increased vascularity has also been shown in ductal carcinoma in situ (DCIS). The prognostic significance of the inflammatory infiltrate in mammary carcinoma is more controversial, but it could affect angiogenesis by releasing angiogenic factors and digesting matrix. Vascularity and inflammation have been studied in 41 examples of pure DCIS, classified using the method of Holland et al. Immunohistochemistry was performed with antibodies to von Willebrand factor, CD3, CD8, CD45RO, CD45RA, CD20, CD68, and c‐erbB‐2. The main pattern of inflammation was clusters of B and T cells situated either adjacent to involved ducts or in the interductal stroma. Typically, these clusters were around vessels with plump endothelium suggestive of high endothelial venules. A less prominent pattern was a diffuse stromal infiltrate of macrophages and T cells. There were two patterns of increased vascularity associated with DCIS: necklaces of vessels close to the involved ducts and vessels arranged diffusely in the interductal stroma. Each pattern of inflammation and of vascularity was graded semi‐quantitatively. Increased stromal vascularity was associated with the perivascular clusters of inflammation; both were associated with c‐erbB‐2 expression and extent of the DCIS. Necklaces of vessels were associated with the diffuse inflammation. Perivascular inflammation and c‐erbB‐2 (but neither pattern of vascularity) were associated with poor differentiation of the DCIS. Thus, different patterns of inflammation are associated with different patterns of vessels. The clusters of B and T cells may be recruited via high endothelial venules induced by the DCIS. Cytokines released by the DCIS and/or the inflammatory cells (clusters or diffuse) may stimulate the two patterns of new vessel formation. © 1997 John Wiley & Sons, Ltd.

[1]  L. Happerfield,et al.  Inflammatory infiltrate in invasive lobular and ductal carcinoma of the breast. , 1996, British Journal of Cancer.

[2]  L. Norton,et al.  Immunophenotype of intraductal carcinoma. , 1996, Archives of pathology & laboratory medicine.

[3]  Anthony J. Guidi,et al.  Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. , 1995, Journal of the National Cancer Institute.

[4]  W. Gregory,et al.  Ductal carcinoma in situ: Assessment of necrosis and nuclear morphology and their association with biological markers , 1995, The Journal of pathology.

[5]  J. Coyne,et al.  Lymphocytic mastopathy associated with ductal carcinoma in situ of the breast , 1995, Histopathology.

[6]  J. Sloane,et al.  neu overexpression correlates with extent of disease in large cell ductal carcinoma in situ of the breast. , 1995, Human pathology.

[7]  P. Validire,et al.  Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity. , 1994, Seminars in diagnostic pathology.

[8]  M. J. van de Vijver,et al.  Ductal carcinoma in situ: a proposal for a new classification. , 1994, Seminars in diagnostic pathology.

[9]  Anthony J. Guidi,et al.  Microvessel density and distribution in ductal carcinoma in situ of the breast. , 1994, Journal of the National Cancer Institute.

[10]  D N Poller,et al.  Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[11]  F. Beuvon,et al.  Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. , 1994, Journal of the National Cancer Institute.

[12]  F Pozza,et al.  Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. , 1992, Journal of the National Cancer Institute.

[13]  A. Harris,et al.  Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer , 1992, The Lancet.

[14]  A. Lee,et al.  Microvessel quantitation and prognosis in invasive breast carcinoma. , 1992, Human pathology.

[15]  V. Kosma,et al.  Lymphocyte infiltrates as a prognostic variable in female breast cancer. , 1992, European journal of cancer.

[16]  S. Ménard,et al.  Prognostic significance of her‐2/neu expression in breast cancer and its relationship to other prognostic factors , 1991, International journal of cancer.

[17]  D. Levison,et al.  Sclerosing lymphocytic lobulitis of the breast–evidence for an autoimmune pathogenesis , 1991, Histopathology.

[18]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[19]  M. Silverstein,et al.  Intraductal carcinoma of the breast (208 cases): Clinical factors influencing treatment choice , 1990, Cancer.

[20]  I. Schwartz,et al.  Lymphocytic mastopathy. An autoimmune disease of the breast? , 1990, American journal of clinical pathology.

[21]  S. Ashley,et al.  Immunohistochemical distribution of c‐erbB‐2 in in situ breast carcinoma—a detailed morphological analysis , 1990, The Journal of pathology.

[22]  F. Breedveld,et al.  Dendritic cells and high endothelial venules in the rheumatoid synovial membrane. , 1990, The Journal of rheumatology.

[23]  H. Drexhage,et al.  High endothelial venules present in lymphoid cell accumulations in thyroids affected by autoimmune disease: a study in men and BB rats of functional activity and development. , 1989, The Journal of clinical endocrinology and metabolism.

[24]  M. J. van de Vijver,et al.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.

[25]  R. Walker,et al.  Immunohistochemical analysis of HLA antigens and mononuclear infiltrates of benign and malignant breast , 1987, The Journal of pathology.

[26]  G. Riethmüller,et al.  Infiltrating mononuclear cells in human breast carcinoma: Predominance of T4+ monocytic cells in the tumor stroma , 1985, International journal of cancer.

[27]  C. Desmarais,et al.  Immunohistologic characterization of major histocompatibility antigens and inflammatory cellular infiltrate in human breast cancer. , 1983, Journal of the National Cancer Institute.

[28]  T. Flotte,et al.  Pathologic predictors of recurrence in stage 1 (TINOMO) breast cancer. , 1982, American journal of clinical pathology.

[29]  W. Dupont,et al.  A retrospective cohort study of histologic risk factors in breast cancer patients , 1982, Cancer.

[30]  J. Haybittle,et al.  The cancer research campaign (King's/Cambridge trial for early breast cancer: clinico-pathological aspects. , 1982, British Journal of Cancer.

[31]  S. Brem,et al.  Angiogenesis as a marker of preneoplastic lesions of the human breast , 1978, Cancer.

[32]  M. Alderson,et al.  The Relative Significance of Prognostic Factors in Breast Carcinoma , 1971, British Journal of Cancer.